AGUAS DA CURIA Aktie - CUR

Professionelle Tools für Privatanleger.

Premium

Current Price

1,17

Gebot

1,17

Fragen

1,17

Volumen

0,00

0,00 Tagesbereich 0,00

1,17 52-Wochen-Bereich 1,17

Handelsende

1,17

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

0,00

Finanzvolumen

VWAP

Neuralstem Completes $5.25 Million Financing

Received NYSE AMEX Notice of Compliance ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE AMEX: CUR) announced today that...

Neuralstem Announces First Patient Treated in ALS Stem Cell Trial

ROCKVILLE, Md., Jan. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its...

Neuralstem Receives Approval To Commence First ALS Stem Cell Trial at Emory ALS Center

ROCKVILLE, Md., Dec. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that its Phase I trial to treat Amyotrophic...

Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update

ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and business update for the third...

Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial

ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

NEW YORK, April 6 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R...

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

Make Synaptic Contact with Host Motor Neurons ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Transplanted human neural stem cells (hNSCs...

Neuralstem's ALS Trial on Clinical Hold

ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today its spinal cord stem cell trial to...

Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board

ROCKVILLE, Md., Feb. 12 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that James Sasser, former Senator...

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President...

Zeitraum †	Handelsbeginn	Hoch	Niedrig
1	1.17	1.17	1.17	DE
4	1.17	1.17	1.17	DE
12	1.17	1.17	1.17	DE
26	1.17	1.17	1.17	DE
52	1.17	1.17	1.17	DE
156	1.17	1.17	1.17	DE
260	1.17	1.17	1.17	DE

CUR - Frequently Asked Questions (FAQ)

What is the current AGUAS DA CURIA share price?

The current share price of AGUAS DA CURIA is 1,17 €

What is the 1 year trading range for AGUAS DA CURIA share price?

AGUAS DA CURIA has traded in the range of 1,17 € to 1,17 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ABCAABC Arbitrage	5,69 € (0,00%)	0
ABAb Science	1,38 € (0,00%)	0
AALBAalberts NV	32,82 € (0,00%)	0
AAAAlan Allman Associates	4,88 € (0,00%)	0
74SW74Software SA	31,60 € (0,00%)	0
ABCAABC Arbitrage	5,69 € (0,00%)	0
ABAb Science	1,38 € (0,00%)	0
AALBAalberts NV	32,82 € (0,00%)	0
AAAAlan Allman Associates	4,88 € (0,00%)	0
74SW74Software SA	31,60 € (0,00%)	0
ABCAABC Arbitrage	5,69 € (0,00%)	0
ABAb Science	1,38 € (0,00%)	0
AALBAalberts NV	32,82 € (0,00%)	0
AAAAlan Allman Associates	4,88 € (0,00%)	0
74SW74Software SA	31,60 € (0,00%)	0

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

AGUAS DA CURIA (CUR)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CUR Neueste Nachrichten

Neuralstem Completes $5.25 Million Financing

Neuralstem Announces First Patient Treated in ALS Stem Cell Trial

Neuralstem Receives Approval To Commence First ALS Stem Cell Trial at Emory ALS Center

Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update

Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

Neuralstem's ALS Trial on Clinical Hold

Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

CUR - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

AGUAS DA CURIA (CUR) Börsenkurse

AGUAS DA CURIA (CUR)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CUR Neueste Nachrichten

Neuralstem Completes $5.25 Million Financing

Neuralstem Announces First Patient Treated in ALS Stem Cell Trial

Neuralstem Receives Approval To Commence First ALS Stem Cell Trial at Emory ALS Center

Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update

Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

Neuralstem's ALS Trial on Clinical Hold

Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

CUR - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen